Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia

Blood

Volumn 116, Issue 2, 2010, Pages 171-179

  Maslak, Peter G ^a   Dao, Tao ^a   Krug, Lee M ^a   Chanel, Suzanne ^a   Korontsvit, Tatyana ^a   Zakhaleva, Victoria ^a   Zhang, Ronghua ^a   Wolchok, Jedd D ^a   Yuan, Jianda ^a   Pinilla Ibarz, Javier ^b   Berman, Ellin ^a   Weiss, Mark ^a   Jurcic, Joseph ^a   Frattini, Mark G ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DAUNORUBICIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; MONTANIDE ISA 51; PEPTIDE VACCINE; POLYVALENT WILMS TUMOR GENE 1 PEPTIDE VACCINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; CANCER VACCINE; HLA A ANTIGEN; HLA A0201 ANTIGEN; HLA-A0201 ANTIGEN; ONCOPROTEIN; SUBUNIT VACCINE; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SECRETION; CLINICAL ARTICLE; CLINICAL TRIAL; DELAYED HYPERSENSITIVITY; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; HUMAN; HYPERSENSITIVITY REACTION; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE IRRITATION; INJECTION SITE PRURITUS; INJECTION SITE REDNESS; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; LARYNX SPASM; MALE; PAIN; PILOT STUDY; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE; URTICARIA; VACCINATION; BIOSYNTHESIS; CYTOTOXICITY; GENETICS; IMMUNOLOGY; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; MORTALITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE-FREE SURVIVAL; FEMALE; HLA-A ANTIGENS; HUMANS; HYPERSENSITIVITY, DELAYED; INTERFERON-GAMMA; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; ONCOGENE PROTEINS; PILOT PROJECTS; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VACCINATION; VACCINES, SUBUNIT; WT1 PROTEINS; YOUNG ADULT;

EID: 77955481538     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-250993     Document Type: Article

References (28)

1. Frattini MG, Maslak PG. Strategy for incorporating molecular and cytogenetic markers into acute myeloid leukemia therapy. J Natl Compr Canc Netw. 2008;6(10):995-1002.
2. Virappane P, Gale R, Hills R, et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008;26(33):5429-5435.
3. Paschka P, Marcucci G, Ruppert AS, et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2008;26(28):4595-4602.
4. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100(6):2132-2137. (Pubitemid 35001248)
5. Rezvani K, Grube M, Brenchley JM, et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood. 2003;102(8):2892-2900.
6. Gillmore R, Xue SA, Holler A, et al. Detection of Wilms' tumor antigen-specific CTL in tumor-draining lymph nodes of patients with early breast cancer. Clin Cancer Res. 2006;12(1):34-42.
7. Rezvani K, Brenchley JM, Price DA, et al. T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization. Clin Cancer Res. 2005;11(24):8799-8807.
8. Rezvani K, Yong AS, Savani BN, et al. Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007;110(6):1924-1932. (Pubitemid 47443906)
9. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A. 2004;101(38):13885-13890.
10. Morita S, Oka Y, Tsuboi A, et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol. 2006;36(4):231-236.
11. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111(1):236-242.
12. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113(26):6541-6548.
13. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica. 2005;90(10):1324-1332. (Pubitemid 41503647)
14. Cathcart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood. 2004;103(3):1037-1042.
15. Maslak PG, Dao T, Gomez M, et al. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia. 2008;22(8):1613-1616.
16. May RJ, Dao T, Pinilla-Ibarz J, et al. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res. 2007;13(15):4547- 4555.
17. Gabert J, Beillard E, van der Velden V, et al. Standardization and quality control studies of "realtime" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: a Europe Against Cancer Program. Leukemia. 2003;17(12):2318-2357. (Pubitemid 38072573)
18. Keilholz U, Menssen HD, Gaiger A, et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia. 2005;19(8):1318-1323.
19. Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21(5):868-876. (Pubitemid 46672061)
20. Gomez-Nunez M, Pinilla-Ibarz J, Dao T, et al. Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leuk Res. 2006;30(10):1293- 1298.
21. Marzo AL, Kinnear BF, Lake RA, et al. Tumorspecific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol. 2000;165(11):6047-6055.
22. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188(12):2357-2368.
23. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54(8):721-728. (Pubitemid 40977140)
24. Guo Y, Niiya H, Azuma T, et al. Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner. Blood. 2005;106(4):1415-1418.
25. Mutti L, Valle MT, Balbi B, et al. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer. 1998;78(6):740-749.
26. Kobayashi H, Nagato T, Aoki N, et al. Defining MHC class II T helper epitopes for WT1 tumor antigen. Cancer Immunol Immunother. 2006;55(7):850-860.
27. Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 2000;95(5):1781-1787.
28. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.